FDA Approves Medtronic BrainSense Adaptive DBS ‘Brain-Computer Interface’ Technology For Parkinson’s Treatment

On February 24, 2025, the U.S. Food and Drug Administration (FDA) approved Medtronic’s BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI) as a treatment to control Parkinson’s disease motor symptoms. The system self-adjusts DBS therapy to the user’s brain activity in real time, which minimizes the need for users to manually adjust the device stimulation to control motor symptom fluctuations, dyskinesias, and other side effects. The BrainSense Adaptive technology is considered a brain-computer interface (BCI).

DBS uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to . . .